Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLaurie H. SehnBC Cancer AgencySYSung‐Soo YoonSeoul National University HospitalNGNorma C. GutiérrezUniversidad de Salamanca

Discussion

Loading...

Member takes

Implication

Phase II trial shows subcutaneous mosunetuzumab achieves durable responses in relapsed follicular lymphoma, suggesting a manageable safety profile with low adverse events.

Key Points

  • Evaluate the efficacy and safety of subcutaneous mosunetuzumab in patients with relapsed/refractory follicular lymphoma after prior therapies.
  • Pivotal Phase II study with patients having Grade 1-3a relapsed/refractory follicular lymphoma.
  • Subcutaneous mosunetuzumab administered in fixed-duration cycles with step-up dosing.
  • Responses assessed based on established clinical criteria, focusing on overall response and safety metrics.
  • Overall response rate was 74%, with a complete response rate of 63%.
  • Median progression-free survival was 18.5 months, with favorable outcomes for complete responders.
  • Cytokine release syndrome occurred in 30% of patients, mostly low-grade, with manageable injection site reactions.

Cite This Study

Sehn et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db57https://doi.org/10.1182/blood-2025-5353
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma2025 · 1 citations
  2. 2Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study2025 · 3 citations
  3. 3Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study2025 · 2 citations
  4. 4Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis2026 · 4 citations
  5. 5Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study2025 · 6 citations